AIM ImmunoTech Inc.

Regulatory Filings • Nov 17, 2025

NT 10-Q 1 formnt10-q.htm NT 10-Q

Field: Rule-Page

Field: /Rule-Page

| | OMB
APPROVAL |
| --- | --- |
| UNITED
STATES SECURITIES
AND EXCHANGE COMMISSION Washington,
D.C. 20549 | OMB
Number: 3235-0058 Expires:
September 30, 2028 Estimated average burden hours
per response 2.50 |
| FORM
12b-25 | SEC
FILE NUMBER |
| | CUSIP
NUMBER |
| NOTIFICATION
OF LATE FILING | |

| (Check
one): | Form
10-K |
| --- | --- |
| For
Period Ended: September 30, 2025 | |
| ☐ | Transition
Report on Form 10-K |
| ☐ | Transition
Report on Form 20-F |
| ☐ | Transition
Report on Form 11-K |
| ☐ | Transition
Report on Form 10-Q |
| For
the Transition Period Ended:_____ | |

| Read
Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing
in this form shall be construed to imply that the Commission has verified any information
contained herein. |
| --- |
| If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: |
| PART
I — REGISTRANT INFORMATION |

| Aim
ImmunoTech Inc. |
| --- |
| Full
Name of Registrant |
| Former
Name if Applicable |
| 2117
SW Highway 484 |
| Address
of Principal Executive Office (Street and Number) |
| Ocala,
FL 34473 |
| City,
State and Zip Code |

SEC 1344 (01-19) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

Board of Governors of the Federal Reserve System 0MB Number 7100-0091 Approval expires February 28, 2026

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

| | (a) | The
reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense; |
| --- | --- | --- |
| ☒ | (b) | The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
| | (c) | The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2025, within the prescribed time due to delays in completing the required review. Additional time is needed for management to compile and verify the data to be included in the report. The Registrant expects to file within the permitted extension period.

(Attach extra Sheets if Needed)

| Robert
Dickey IV | 610 | 864-6470 |
| --- | --- | --- |
| (Name) | (Area
Code) | (Telephone
Number) |

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☒ No ☐

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. See attached.

Field: Page; Sequence: 2; Options: NewSection; Value: 2

2 of 4

Field: /Page

Aim ImmunoTech Inc.

Field: Rule-Page

Field: /Rule-Page

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date
Robert Dickey IV
Chief
Financial Officer

INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the Form.

Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

GENERAL INSTRUCTIONS

| 1. | This
Form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations
under the Securities Exchange Act of 1934. |
| --- | --- |
| 2. | One
signed original and four conformed copies of this Form and amendments thereto must be completed
and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance
with Rule 0-3 of the General Rules and Regulations under the Act. The information contained
in or filed with the Form will be made a matter of public record in the Commission files. |
| 3. | A
manually signed copy of the Form and amendments thereto shall be filed with each national
securities exchange on which any class of securities of the registrant is registered. |
| 4. | Amendments
to the notifications must also be filed on Form 12b-25 but need not restate information that
has been correctly furnished. The Form shall be clearly identified as an amended notification. |
| 5. | Electronic
filers. This form shall not be used by electronic filers unable to timely file a report solely
due to electronic difficulties. Filers unable to submit a report within the time period prescribed
due to difficulties in electronic filing should comply with either Rule 201 or Rule 202 of
Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment
in filing date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this Chapter). |
| 6. | Interactive
data submissions . This Form shall not be used by electronic filers with respect to the submission or posting of an Interactive
Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time period
prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter). |

Field: Page; Sequence: 3; Value: 2

3 of 4

Field: /Page

ATTACHMENT TO PART IV-ITEM (3) OF FORM 12B-25

AIM ImmunoTech, Inc.

WITH RESPECT TO ITS FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2025

The Registrant estimates that its results of operations for the period ended September 30, 2025, as reflected in its consolidated statements of operations to be included in its Form 10-Q for the period ended September 30, 2025, will reflect the following changes:

For the three month period ended September 30, 2025, the Registrant expects to report a decrease in revenues to approximately $26,000 from approximately $35,000 for the three month period ended September 30, 2024. For the nine month period ended September 30, 2025, the Registrant expects to report a decrease in revenues to approximately $67,000 from approximately $125,000 for the nine month period ended September 30, 2024. Also, for the three month period ended September 30, 2025, the Registrant expects to report a net loss of approximately $3,284,000 compared to a net loss of approximately $3,700,000 for the three month period ended September 30, 2024. For the nine month period ended September 30, 2025, the Registrant expects to report a net loss of approximately $9,783,000 as compared to a net loss of approximately $11,353,000 for the nine month period ended September 30, 2024.

Finally, for the three month period ended September 30, 2025, the Registrant expects to report net loss per share - basic and diluted - of approximately $(1.57) compared to net loss per share – basic and diluted - of $(6.00) for the three month period ended September 30, 2024. For the nine month period ended September 30, 2025, the Registrant expects to report net loss per share - basic and diluted - of approximately $(8.18) compared to net loss per share – basic and diluted - of $(21.00) for the nine month period ended September 30, 2024.

Field: Page; Sequence: 4; Options: Last

4 of 4

Field: /Page